The Cystic Fibrosis Foundation (CFF) has awarded Synspira Therapeutics up to $14 million in additional funding for development of two Synspira candidates including SNSP113, an inhaled polycationic glycopolymer for the treatment of CF. The foundation had previously awarded Synspira $8.55 million in 2017.
SNSP113, which is currently in Phase 2 development, received orphan drug designation from the FDA in October 2018 and from the EU in April 2019. According to CFF, SNSP113 is “an inhaled treatment that could address difficult-to-treat infections, reduce inflammation in the lungs, and thin mucus.”
CFF President and CEO Michael Boyle said, “Despite the approval of new treatments for the underlying cause of CF, many people will continue to need therapies to address challenges such as pancreatic insufficiency and pulmonary complications. We are hopeful that these novel products will someday help address some of the persistent medical challenges that are still faced by people who are now living longer with CF.”
Synspira President and CEO Robert Gallotto commented, “This investment and development collaboration will enable Synspira to complete preclinical and initial clinical development for SNSP003 while also advancing SNSP113 through late stage clinical studies. Our many longstanding collaborations with the CF Foundation underscores our commitment and mutual sense of urgency as we work to bring life-changing therapies to people living with CF and other serious rare disorders.”
Read the Cystic Fibrosis Foundation press release.
Read the Synspira Therapeutics press release.
